the effects of Medicare’s drug price negotiation, Lilly’s recent disappointing guidance, pricing of the company’s obesity medication Zepbound, and more. We also discuss the latest news from ...

Lilly's stock went on a tear in the beginning of 2023, with the company's shares doubling as investors bet on the drug's popularity. The stock stumbled in October last year, after Zepbound's sales ...